{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:45:33Z","timestamp":1793400333195,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T00:00:00Z","timestamp":1650931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T00:00:00Z","timestamp":1650931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006407","name":"Natural Science Foundation of Henan Province","doi-asserted-by":"publisher","award":["182300410301"],"award-info":[{"award-number":["182300410301"]}],"id":[{"id":"10.13039\/501100006407","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Henan Provincial Medical Scientific Research Fund","award":["201403029"],"award-info":[{"award-number":["201403029"]}]},{"name":"the Key Scientific Research Project of Higher\u2002Education\u2002of\u2002Henan Province","award":["18A320050"],"award-info":[{"award-number":["18A320050"]}]},{"name":"Science and Technology Plan of Henan Province","award":["182102310160"],"award-info":[{"award-number":["182102310160"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Myeloid sarcoma is a rare manifestation of acute myeloid leukemia (AML) and is associated with poor overall survival (OS). The optimal treatment remains unclear. The study retrospectively evaluated 118 patients with myeloid sarcoma who were treated at the First Affiliated Hospital of Zhengzhou University from January 2010 to July 2021. All cases were diagnosed by tissue biopsy. 41 patients underwent genetic mutation analysis. The most frequent genetic mutations were\n                    <jats:italic>KIT<\/jats:italic>\n                    (16.6%), followed by\n                    <jats:italic>TET2<\/jats:italic>\n                    (14.6%), and\n                    <jats:italic>NRAS<\/jats:italic>\n                    (14.6%). The median survival time of 118 patients was 4\u00a0months (range, 1\u201351\u00a0months), while the median survival time of 11 patients who received allogeneic hematopoietic stem cell transplantation (allo-HSCT) was 19\u00a0months (range, 8\u201351\u00a0months). 4 (36.4%) of the 11 patients experienced relapse within 1\u00a0year after transplantation. 1 patient died from a severe infection. Of the 6 surviving patients, 5 patients have received maintenance treatment with decitabine after transplantation, and all remained in a state of recurrence-free survival. Patients with myeloid sarcoma have a very unfavorable outcome. Allo-HSCT is an effective treatment option. Recurrence remains the main cause of transplant failure. Maintenance treatment with decitabine after transplantation can prolong the recurrence-free survival time, although these results must be verified in a study with expanded sample size.\n                  <\/jats:p>","DOI":"10.1038\/s41598-022-10831-7","type":"journal-article","created":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T06:09:28Z","timestamp":1650953368000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Clinical characteristics, treatment, and prognosis of 118 cases of myeloid sarcoma"],"prefix":"10.1038","volume":"12","author":[{"given":"Haiqiu","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenkun","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingming","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijie","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haizhou","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jixin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqiong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runqing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinyin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongxing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinsheng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,26]]},"reference":[{"key":"10831_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber, D. A. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127, 2391\u20132405 (2016).","journal-title":"Blood"},{"key":"10831_CR2","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1097\/PAS.0000000000000727","volume":"40","author":"K Kawamoto","year":"2016","unstructured":"Kawamoto, K. et al. Clinicopathological, cytogenetic, and prognostic analysis of 131 myeloid sarcoma patients. Am. J. Surg. Pathol. 40, 1473\u20131483 (2016).","journal-title":"Am. J. Surg. Pathol."},{"key":"10831_CR3","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1182\/blood-2011-04-347229","volume":"118","author":"RL Bakst","year":"2011","unstructured":"Bakst, R. L., Tallman, M. S., Douer, D. & Yahalom, J. How I treat extramedullary acute myeloid leukemia. Blood 118, 3785\u20133793 (2011).","journal-title":"Blood"},{"key":"10831_CR4","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1038\/leu.2012.156","volume":"26","author":"H Shimizu","year":"2012","unstructured":"Shimizu, H. et al. Allogeneic hematopoietic stem cell transplantation for adult AML patients with granulocytic sarcoma. Leukemia 26, 2469\u20132473 (2012).","journal-title":"Leukemia"},{"key":"10831_CR5","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1080\/10428190600632857","volume":"47","author":"I Cunningham","year":"2006","unstructured":"Cunningham, I. Extramedullary sites of leukemia relapse after transplant. Leuk. Lymphoma 47, 1754\u20131767 (2006).","journal-title":"Leuk. Lymphoma"},{"key":"10831_CR6","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.cell.2006.05.051","volume":"126","author":"C Murgia","year":"2006","unstructured":"Murgia, C., Pritchard, J. K., Kim, S. Y., Fassati, A. & Weiss, R. A. Clonal origin and evolution of a transmissible cancer. Cell 126, 477\u2013487 (2006).","journal-title":"Cell"},{"key":"10831_CR7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3390\/cancers12010069","volume":"12","author":"P Bernasconi","year":"2019","unstructured":"Bernasconi, P. & Borsani, O. Immune escape after hematopoietic stem cell transplantation (HSCT): From mechanisms to novel therapies. Cancers (Basel) 12, 69 (2019).","journal-title":"Cancers (Basel)"},{"key":"10831_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.624742","volume":"11","author":"KK Wong","year":"2021","unstructured":"Wong, K. K., Hassan, R. & Yaacob, N. S. Hypomethylating agents and immunotherapy: Therapeutic synergism in acute myeloid leukemia and myelodysplastic syndromes. Front. Oncol. 11, 624742 (2021).","journal-title":"Front. Oncol."},{"key":"10831_CR9","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.1200\/JCO.19.03277","volume":"38","author":"L Gao","year":"2020","unstructured":"Gao, L. et al. Effect of rhG-CSF combined with decitabine prophylaxis on relapse of patients with high-risk MRD-negative AML after HSCT: An open-label, multicenter, randomized controlled trial. J. Clin. Oncol. 38, 4249\u20134259 (2020).","journal-title":"J. Clin. Oncol."},{"key":"10831_CR10","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/j.bbmt.2015.05.026","volume":"21","author":"I Pusic","year":"2015","unstructured":"Pusic, I. et al. Maintenance therapy with decitabine after allogeneic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. Biol. Blood Marrow Transplant. 21, 1761\u20131769 (2015).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10831_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.710545","volume":"11","author":"J Liu","year":"2021","unstructured":"Liu, J. et al. Maintenance treatment with low-dose decitabine after allogeneic hematopoietic cell transplantation in patients with adult acute lymphoblastic leukemia. Front. Oncol. 11, 710545 (2021).","journal-title":"Front. Oncol."},{"key":"10831_CR12","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/sj.leu.2404491","volume":"21","author":"SA Pileri","year":"2007","unstructured":"Pileri, S. A. et al. Myeloid sarcoma: Clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia 21, 340\u2013350 (2007).","journal-title":"Leukemia"},{"key":"10831_CR13","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s12891-021-04066-2","volume":"22","author":"CR Bai","year":"2021","unstructured":"Bai, C. R. et al. Diagnosis and surgical treatment of primary isolated aggressive lumbar myeloid sarcoma: A rare case report and review of the literatures. BMC Musculoskelet. Disord. 22, 220 (2021).","journal-title":"BMC Musculoskelet. Disord."},{"key":"10831_CR14","volume":"12","author":"M Kumar","year":"2020","unstructured":"Kumar, M., Sonia, F., Hamadani, S. M. & Abbas, S. A. A rare case of acute cord compression from spinal myeloid sarcoma: A complication of acute myeloid leukemia. Cureus 12, e9502 (2020).","journal-title":"Cureus"},{"key":"10831_CR15","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/S0140-6736(12)60352-3","volume":"380","author":"N Kumar","year":"2012","unstructured":"Kumar, N., Yadav, S., Reddy, V. & Robert, F. Leukaemia cutis. Lancet 380, 1179 (2012).","journal-title":"Lancet"},{"key":"10831_CR16","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s11912-020-00919-6","volume":"22","author":"R Bakst","year":"2020","unstructured":"Bakst, R., Powers, A. & Yahalom, J. Diagnostic and therapeutic considerations for extramedullary leukemia. Curr. Oncol. Rep. 22, 75 (2020).","journal-title":"Curr. Oncol. Rep."},{"key":"10831_CR17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1080\/08880018.2020.1803462","volume":"38","author":"G Hu","year":"2021","unstructured":"Hu, G. et al. Characteristics and prognosis of pediatric myeloid sarcoma in the cytogenetic context of t(8;21). Pediatr. Hematol. Oncol. 38, 14\u201324 (2021).","journal-title":"Pediatr. Hematol. Oncol."},{"key":"10831_CR18","first-page":"333","volume":"153","author":"JC Dalland","year":"2020","unstructured":"Dalland, J. C., Meyer, R., Ketterling, R. P. & Reichard, K. K. Myeloid sarcoma with CBFB-MYH11 fusion (inv(16) or t(16;16)) prevails in the abdomen. Am. J. Clin. Pathol. 153, 333\u2013341 (2020).","journal-title":"Am. J. Clin. Pathol."},{"key":"10831_CR19","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.1182\/blood-2005-09-3640","volume":"107","author":"R Cairoli","year":"2006","unstructured":"Cairoli, R. et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: An Italian retrospective study. Blood 107, 3463\u20133468 (2006).","journal-title":"Blood"},{"key":"10831_CR20","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1007\/s00277-017-3074-y","volume":"96","author":"S Yui","year":"2017","unstructured":"Yui, S. et al. D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations. Ann. Hematol. 96, 1641\u20131652 (2017).","journal-title":"Ann. Hematol."},{"key":"10831_CR21","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.3892\/ol.2020.11479","volume":"19","author":"J Wang","year":"2020","unstructured":"Wang, J. et al. Characteristics of myeloid sarcoma in mice and patients with TET2 deficiency. Oncol. Lett. 19, 3789\u20133798. https:\/\/doi.org\/10.3892\/ol.2020.11479 (2020).","journal-title":"Oncol. Lett."},{"key":"10831_CR22","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1007\/s12185-021-03081-2","volume":"113","author":"M Shan","year":"2021","unstructured":"Shan, M. et al. Characteristics and transplant outcome of myeloid sarcoma: A single-institute study. Int. J. Hematol. 113, 682\u2013392 (2021).","journal-title":"Int. J. Hematol."},{"key":"10831_CR23","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1038\/s41409-021-01250-9","volume":"56","author":"H Sakaguchi","year":"2021","unstructured":"Sakaguchi, H. et al. Effect of extramedullary disease on allogeneic hematopoietic cell transplantation for pediatric acute myeloid leukemia: A nationwide retrospective study. Bone Marrow Transplant. 56, 1859\u20131865 (2021).","journal-title":"Bone Marrow Transplant."},{"key":"10831_CR24","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41409-020-0984-4","volume":"56","author":"JJ Frietsch","year":"2021","unstructured":"Frietsch, J. J. et al. Extra-medullary recurrence of myeloid leukemia as myeloid sarcoma after allogeneic stem cell transplantation: Impact of conditioning intensity. Bone Marrow Transplant. 56, 101\u2013109 (2021).","journal-title":"Bone Marrow Transplant."},{"key":"10831_CR25","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/ejh.12909","volume":"99","author":"C Bourlon","year":"2017","unstructured":"Bourlon, C. et al. Extramedullary disease at diagnosis of AML does not influence outcome of patients undergoing allogeneic hematopoietic cell transplant in CR1. Eur. J. Haematol. 99, 234\u2013239 (2017).","journal-title":"Eur. J. Haematol."},{"key":"10831_CR26","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00277-020-04383-x","volume":"100","author":"WJ Yu","year":"2021","unstructured":"Yu, W. J. et al. Haploidentical hematopoietic stem cell transplantation for patients with myeloid sarcoma: A single center retrospective study. Ann. Hematol. 100, 799\u2013808 (2021).","journal-title":"Ann. Hematol."},{"key":"10831_CR27","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3960\/jslrt.53.235","volume":"53","author":"T Matsui","year":"2013","unstructured":"Matsui, T., Hidaka, M., Kiyokawa, T., Murayama, T. & Kawano, F. Successful treatment of bulky granulocytic sarcoma of the retroperitoneum with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. J. Clin. Exp. Hematopathol. 53, 235\u2013239 (2013).","journal-title":"J. Clin. Exp. Hematopathol."},{"key":"10831_CR28","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1159\/000455998","volume":"137","author":"Y Liang","year":"2017","unstructured":"Liang, Y. et al. Long-term remission following autologous hematopoietic cell transplantation in a patient with multiple nonleukemic myeloid sarcoma and a review of the literature. Acta Haematol. 137, 117\u2013122 (2017).","journal-title":"Acta Haematol."},{"key":"10831_CR29","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/bjh.15818","volume":"185","author":"MR Nahas","year":"2019","unstructured":"Nahas, M. R. et al. Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell\/AML vaccine. Br. J. Haematol. 185, 679\u2013690 (2019).","journal-title":"Br. J. Haematol."},{"key":"10831_CR30","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1620\/tjem.254.101","volume":"254","author":"H Okamoto","year":"2021","unstructured":"Okamoto, H. et al. Durable remission of chemotherapy-refractory myeloid sarcoma by azacitidine. Tohoku J. Exp. Med. 254, 101\u2013105 (2021).","journal-title":"Tohoku J. Exp. Med."},{"key":"10831_CR31","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000007975","volume":"96","author":"T Katagiri","year":"2017","unstructured":"Katagiri, T. et al. Successful 5-azacytidine treatment of myeloid sarcoma and leukemia cutis associated with myelodysplastic syndrome: A case report and literature review. Medicine (Baltimore) 96, e7975 (2017).","journal-title":"Medicine (Baltimore)"},{"key":"10831_CR32","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3390\/diagnostics9030084","volume":"9","author":"C Minoia","year":"2019","unstructured":"Minoia, C. et al. Long-lasting remission in de novo breast myeloid sarcoma treated with decitabine and radiotherapy. Diagnostics (Basel) 9, 84 (2019).","journal-title":"Diagnostics (Basel)"},{"key":"10831_CR33","first-page":"694","volume":"41","author":"FQ Tian","year":"2020","unstructured":"Tian, F. Q. et al. Venetoclax combined with azacitidine in the treatment of elderly patients with acute myeloid leukemia or myeloid sarcoma: Three cases reports and literature review. Zhonghua Xue Ye Xue Za Zhi 41, 694\u2013696 (2020).","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10831_CR34","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.it.2006.07.007","volume":"27","author":"KL Wright","year":"2006","unstructured":"Wright, K. L. & Ting, J. P. Epigenetic regulation of MHC-II and CIITA genes. Trends Immunol. 27, 405\u2013412 (2006).","journal-title":"Trends Immunol."},{"key":"10831_CR35","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41591-019-0400-z","volume":"25","author":"C Toffalori","year":"2019","unstructured":"Toffalori, C. et al. Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. Nat. Med. 25, 603\u2013611 (2019).","journal-title":"Nat. Med."},{"key":"10831_CR36","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1016\/j.bbmt.2018.06.016","volume":"24","author":"M de Lima","year":"2018","unstructured":"de Lima, M. et al. CC-486 maintenance after stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndromes. Biol. Blood Marrow Transplant. 24, 2017\u20132024 (2018).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10831_CR37","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s12185-018-2470-y","volume":"108","author":"D Evers","year":"2018","unstructured":"Evers, D., Bar, B., Gotthardt, M. & van der Velden, W. Activity of decitabine in pericardial myeloid sarcoma. Int. J. Hematol. 108, 121\u2013122 (2018).","journal-title":"Int. J. Hematol."},{"key":"10831_CR38","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/bmt.2012.256","volume":"48","author":"A Antar","year":"2013","unstructured":"Antar, A. et al. Azacitidine in the treatment of extramedullary relapse of AML after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 48, 994\u2013995 (2013).","journal-title":"Bone Marrow Transplant."},{"key":"10831_CR39","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1038\/bmt.2011.210","volume":"47","author":"SN Singh","year":"2012","unstructured":"Singh, S. N., Cao, Q., Gojo, I., Rapoport, A. P. & Akpek, G. Durable complete remission after single agent decitabine in AML relapsing in extramedullary sites after allo-SCT. Bone Marrow Transplant. 47, 1008\u20131009 (2012).","journal-title":"Bone Marrow Transplant."},{"key":"10831_CR40","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.3389\/fphar.2018.01279","volume":"9","author":"D Heudobler","year":"2018","unstructured":"Heudobler, D. et al. cutaneous leukemic infiltrates successfully treated with biomodulatory therapy in a rare case of therapy-related high risk MDS\/AML. Front. Pharmacol. 9, 1279 (2018).","journal-title":"Front. Pharmacol."},{"key":"10831_CR41","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1200\/JOP.18.00753","volume":"15","author":"AS Kanate","year":"2019","unstructured":"Kanate, A. S., Vos, J. & Chargualaf, M. J. Venetoclax for refractory myeloid sarcoma. J. Oncol. Pract. 15, 413\u2013415 (2019).","journal-title":"J. Oncol. Pract."},{"key":"10831_CR42","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s12185-020-02855-4","volume":"112","author":"M Kida","year":"2020","unstructured":"Kida, M. et al. Successful treatment with gilteritinib for isolated extramedullary relapse of acute myeloid leukemia with FLT3-ITD mutation after allogeneic stem cell transplantation. Int. J. Hematol. 112, 243\u2013248 (2020).","journal-title":"Int. J. Hematol."},{"key":"10831_CR43","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1056\/NEJMoa1601202","volume":"375","author":"MS Davids","year":"2016","unstructured":"Davids, M. S. et al. Ipilimumab for patients with relapse after allogeneic transplantation. N. Engl. J. Med. 375, 143\u2013153 (2016).","journal-title":"N. Engl. J. Med."},{"key":"10831_CR44","doi-asserted-by":"publisher","first-page":"e174","DOI":"10.1097\/MPH.0000000000001201","volume":"41","author":"MJ McNeil","year":"2019","unstructured":"McNeil, M. J. et al. Clinical and radiographic response of extramedullary leukemia in patients treated with gemtuzumab ozogamicin. J. Pediatr. Hematol. Oncol. 41, e174\u2013e176 (2019).","journal-title":"J. Pediatr. Hematol. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10831-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10831-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10831-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T21:07:49Z","timestamp":1669324069000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10831-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,26]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10831"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-10831-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,26]]},"assertion":[{"value":"21 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6752"}}